Specific interaction of VEGF165 with β-amyloid, and its protective effect on β-amyloid-induced neurotoxicity

Journal of Neurochemistry

Volumn 93, Issue 1, 2005, Pages 118-127

  Yang, Seung Pil ^a   Kwon, Byoung Oh ^a   Gho, Yong Song ^a   Chae, Chi Bom ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

amyloid; Alzheimer's disease; Cytotoxicity; Heparin binding domain; Reactive oxygen species; Vascular endothelial growth factor

Indexed keywords

AMYLOID BETA PROTEIN; FIBROBLAST GROWTH FACTOR; ISOPROTEIN; MIDKINE; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); CARRIER PROTEIN; CYTOKINE; PEPTIDE FRAGMENT; PLEIOTROPHIN; RECOMBINANT PROTEIN; VASCULOTROPIN A;

ANIMAL CELL; ARTICLE; BRAIN; CARBOXY TERMINAL SEQUENCE; CELL STRAIN; CONTROLLED STUDY; CYTOTOXICITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SENILE PLAQUE; ANIMAL; BINDING SITE; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; RAT; SEQUENCE HOMOLOGY; SURFACE PLASMON RESONANCE; TIME;

AMYLOID BETA-PROTEIN; ANIMALS; BINDING SITES; CARRIER PROTEINS; CELL SURVIVAL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PC12 CELLS; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN ISOFORMS; RATS; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SURFACE PLASMON RESONANCE; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 16244376148     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02993.x     Document Type: Article

References (41)

1. Asai T., Watanabe K., Ichihara-Tanaka K., Kaneda N., Kojima S., Iguchi A., Inagaki F. and Muramatsu T. (1997) Identification of heparin-binding sites in midkine and their role in neurite-promotion. Biochem. Biophys. Res. Commun. 236, 66-70.
2. Bacic M., Edwards N. A. and Merrill M. J. (1995) Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Growth Factors 12, 11-15.
3. Bae D. G., Gho Y. S., Yoon W. H. and Chae C.-B. (2000) Arginine-rich antivascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J. Biol. Chem. 275, 13588-13596.
4. Bashkir P., Doctrow S., Klagsbrun M., Svahn C. M., Folkman J. and Vlodavsky J. (1989) Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28, 1737-1743.
5. Behl C., Davis J. B., Lesley R. and Schubert D. (1994) Hydrogen peroxide mediates amyloid β protein toxicity. Cell 77, 817-827.
6. Butterfield D. A., Drake J., Pocernich C. and Castegna A. (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β peptide. Trends Mol. Med. 7, 548-554.
7. Du Y., Bales K. R., Dodel R. C., Liu X., Glinn M. A., Horn J. W., Little S.P. and Paul S. M. (1998) α2-Macroglobuline attenuates β-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. J. Neurochem. 70, 1182-1188.
8. Fairbrother W. J., Champe M. A., Christinger H. W., Keyt B. A. and Starovasnik M. A. (1998) Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure 6, 637-648.
9. Ferrara N. (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280, C1358-C1366.
10. Ferrara N., Houck K., Jakeman L. and Leung D. W. (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev. 13, 18-32.
11. Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
12. Hewlett D. R., Jennings K. H., Lee D. C., Clark M. S., Brown F., Wetzel R., Wood S. J., Camilleri P. and Roberts G. W. (1995) Aggregation state and neurotoxic properties of Alzheimer β-amyloid peptide. Neurodegeneration 4, 23-32.
13. Hughes S. R., Khorkova O., Goyal S., Knaeblein J., Heroux J., Riedel N. G. and Sahasrabudhe S. (1998) β2-Macroglobulin associates with β-amyloid peptide and prevents fibril formation. Proc. Natl Acad. Sci. USA 95, 3275-3280.
14. Jarrett J. T., Berger E. P. and Lansbury P. T. Jr (1993) The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697.
15. Jin K. L., Mao X. O. and Greenberg D. A. (2000) Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc. Natl Acad. Sci. USA 97, 10 242-10 247.
16. Keck R. G., Berleau L., Harris R. and Keyt B. A. (1997) Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of post-translational modifications in VEGF. Arch. Biochem. Biophys. 344, 103-113.
17. Keyt B. A., Berleau L. T., Nguyen H. V., Chen H., Heinsohn H., Vandlen R. and Ferrara N. (1996) The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271, 7788-7795.
18. Khachigian L. M., Owensby D. A. and Chesterman C. N. (1992) A tyrosinated peptide representing the alternatively spliced exon of the platelet-derived growth factor A-chain binds specifically to cultured cells and interferes with binding of several growth factors. J. Biol. Chem. 267, 1660-1666.
19. LeVine H. III (1993) Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2, 404-410.
20. Lyon M., Deakin J. A., Mizuno K., Nakamura T. and Gallagher J. T. (1994) Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J. Biol. Chem. 269, 11 216-11 223.
21. Matsubara E., Soto C., Governale S., Frangione B. and Ghiso J. (1996) Apolipoprotein J and Alzheimer's amyloid solubility. Biochem. J. 316, 671-679.
22. Matsuzaki H., Tamatani M., Yamaguchi A., Namikawa K., Kiyama H., Vitek M. P., Mitsuda M. and Tohyama M. (2001) Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades. FASEB J. 15, 1218-1220.
23. Mudher A. and Lovestone S. (2002) Alzheimer's disease: do tauists and baptists finally shake hands? Trends Neurosci. 25, 22-26.
24. Ogunshola O. O., Antic A., Donoghue M. J., Fan S. Y., Kim H., Stewart W. B., Madri J. A. and Ment L. R. (2002) Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system. J. Biol. Chem. 277, 11 410-11 415.
25. Pike C. J., Burdick D., Walencewicz A. J., Globe C. G. and Cotman C. W. (1993) Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676-1687.
26. Pike C. J., Overman M. J. and Cotman C. W. (1995) Amino-terminal deletions enhance aggregation of β-amyloid peptides in vitro. J. Biol. Chem. 270, 23 895-23 898.
27. Shearman M. S., Hawtin S. R. and Tailor V. J. (1995) The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) reduction is specifically inhibited by β-amyloid peptides. J. Neurochem. 65, 218-227.
28. Soker S., Gollamudi-Payne S., Fidder H., Charmahelli H. and Klagsbrun M. (1996) Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J. Biol. Chem. 272, 31 582-31 588.
29. Soker S., Takashima S., Miao H. Q., Neufeld G. and Klagsbrun M. (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745.
30. Sommer B. (2002) Alzheimer's disease and the amyloid cascade hypothesis: 10 years on. Curr. Opin. Pharmacol. 2, 87-92.
31. Taipale J. and Keski-Oja J. (1997) Growth factors in the extracellular matrix. FASEB J. 11, 51-59.
32. Thomas K. A. (1996) Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 271, 603-606.
33. Tjernberg L. O., Naslund J., Lindqvist F., Johansson J., Karlstrom A. R., Thyberg J., Terenius L. and Nordstedt C. (1996) Arrest of β-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271, 8545-8548.
34. Wisniewski T., Castano E. M., Golabek A., Vogel T. and Frangione B. (1994) Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145, 1030-1035.
35. Yamada M. (2000) Cerebral amyloid angiopathy: an overview. Neuropathology 20, 8-22.
36. Yancopoulos G. D., Davis S., Gale N. W., Rudge J. S., Wiegand S. J. and Holash J. (2000) Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248.
37. Yang S.-P., Bae D. G., Kang H. J., Gwag B. J., Gho Y. S. and Chae C.-B. (2004) Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging 25, 283-290.
38. Yankner B. A. (1996) Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16, 921-932.
39. Yankner B. A., Duffy L. K. and Kirschner D. A. (1990) Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 250, 279-282.
40. Yasuhara O., Muramatsu H., Kim S. U., Muramatsu T., Maruta H. and McGeer P. L. (1993) Midkine, a novel neurotrophic factor, is present in senile plaques of Alzheimer disease. Biochem. Biophys. Res. Commun. 192, 246-251.
41. Yu G. S., Hu J. and Nakagawa H. (1998) Inhibition of β-amyloid cytotoxicity by midkine. Neurosci. Lett. 254, 125-128.